Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Phase 1

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: ABT-199
Drug: bortezomib
Drug: dexamethasone

First Posted Date: 2013-02-20

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie

Target Recruit Count: 66

Registration Number: NCT01794507

Locations: 🇺🇸
University of Arizona Cancer Center - North Campus /ID# 117876, Tucson, Arizona, United States
🇺🇸
Mayo Clinic /ID# 121495, Jacksonville, Florida, United States
🇦🇺
Peter MacCallum Cancer Ctr /ID# 79553, Melbourne, Victoria, Australia

and more 6 locations

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Venetoclax
Drug: Dexamethasone

First Posted Date: 2013-02-20

Last Posted Date: 2023-04-10

Lead Sponsor: AbbVie

Target Recruit Count: 117

Registration Number: NCT01794520

Locations: 🇺🇸
Medical College of Wisconsin /ID# 205229, Milwaukee, Wisconsin, United States
🇺🇸
Mayo Clinic - Rochester /ID# 74994, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic - Scottsdale /ID# 75808, Scottsdale, Arizona, United States

and more 26 locations

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2013-02-18

Last Posted Date: 2018-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 9

Registration Number: NCT01794039

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Phase 1

Completed

Conditions: Amyloidosis
Systemic Light Chain Amyloidosis

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2013-02-12

Last Posted Date: 2017-10-18

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 32

Registration Number: NCT01789242

Locations: 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 7 locations

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

Not Applicable

Terminated

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone

First Posted Date: 2013-02-11

Last Posted Date: 2020-03-12

Lead Sponsor: Lahey Clinic

Target Recruit Count: 3

Registration Number: NCT01788475

Locations: 🇺🇸
Lahey Medical Center, One Essex Center Drive, Peabody, Massachusetts, United States

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2013-02-04

Last Posted Date: 2018-10-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT01782963

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Systane Ultra Versus Maxidex Versus Saline

Not Applicable

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Systane Ultra
Drug: Saline solution
Drug: Maxidex

First Posted Date: 2013-01-25

Last Posted Date: 2013-01-25

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 36

Registration Number: NCT01775540

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

PRevention of Macular EDema After Cataract Surgery

Phase 3

Completed

Conditions: Cystoid Macular Edema
Diabetes Mellitus
Cataract

Interventions: Drug: Bromfenac
Drug: Dexamethasone
Drug: Triamcinolone Acetonide
Drug: Bevacizumab

First Posted Date: 2013-01-24

Last Posted Date: 2017-04-14

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 1127

Registration Number: NCT01774474

Locations: 🇦🇹
Hospital of the Brothers of Saint John of God, Vienna, Austria
🇧🇪
University Hospital Antwerp, Edegem, Belgium
🇳🇱
Academic Medical Center, Amsterdam, Netherlands

and more 13 locations